- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04551170
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
April 1, 2024 updated by: Ashley Shoemaker, Vanderbilt University Medical Center
Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism
Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones.
This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism.
We hypothesize that theophylline will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance in children.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Pseudohypoparathyroidism (PHP) is a rare, genetic disorder caused by impaired stimulatory G protein (Gsα) signaling through downregulation of the gene, GNAS.
The resultant hormone abnormalities can be treated with hormone replacement therapy, but other aspects of the disorder such as early-onset obesity and short stature are without effective treatment options.
Gsα signaling is essential for the normal hormonal function of the pituitary, thyroid, gonads, renal proximal tubules and hypothalamus.
While many of the resulting hormone deficiencies can be treated with hormone replacement therapy (HRT), HRT is not an effective therapy for the severe early-onset obesity and short stature which are major features of the PHP phenotype.
Therefore, the goal of this clinical trial is to test the efficacy of upstream therapy aimed at correcting the function of Gsα-dependent receptors in children with PHP.
Gsα-coupled receptor signaling cascade begins with an increase in cyclic adenosine monophosphate (cAMP) which is rapidly degraded by the enzyme phosphodiesterase (PDE).
PDE inhibitors act by prolonging cAMP signaling by decreasing the rate of degradation.
Given that patients with PHP have reduced, but not completely absent, cAMP production, the investigators seek to test the hypothesis that the PDE inhibitor theophylline will reduce body mass index (BMI), slow the rate of epiphyseal closure, and decrease hormone resistance in children with PHP through improved Gsα-coupled receptor signaling.
The investigators will conduct a 52-week randomized, placebo-controlled clinical trial of theophylline in children with PHP.
Theophylline is a non-selective PDE inhibitor that is generically available and has a long history of use in pediatric patients, making it an ideal drug for repurposing in youth with PHP.
Furthermore, the pharmacokinetics of theophylline are well understood, and serum drug levels are easily measured.
Our primary outcome is change in BMI.
Secondary outcome measures include change in epiphyseal closure and HRT medication doses.
Study Type
Interventional
Enrollment (Estimated)
34
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ashley Shoemaker, MD
- Phone Number: 6153438116
- Email: ashley.h.shoemaker@vumc.org
Study Contact Backup
- Name: Jenny Leshko, RN
- Phone Number: 6153438116
- Email: jenny.leshko@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Recruiting
- Vanderbilt University Medical Center
-
Contact:
- Ashley Shoemaker, M.D.
- Phone Number: 615-343-8116
- Email: ashley.h.shoemaker@vumc.org
-
Principal Investigator:
- Ashley Shoemaker, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 months to 10 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 2 to 12 years old
- Clinical diagnosis of PHP (per the EuroPHP network classification guidelines5): Presence of PTH resistance and/or ectopic ossification OR brachydactyly type E plus 2 minor criteria (TSH resistance, other hormonal resistance, developmental delay, intrauterine or post-natal growth retardation, obesity/overweight, specific facial features)
- Obesity (BMI >95th percentile for age/gender and/or ≥30 kg/m2)
Exclusion Criteria:
- Use of a PDE inhibitor in the past 30 days
- History of a seizure disorder unrelated to hypocalcemia
- History of a cardiac arrhythmia (not including bradycardia)
- Hepatic insufficiency including cirrhosis and acute hepatitis (AST or ALT >3x upper limit of normal)
- Congestive heart failure
- Current cigarette use or alcohol abuse
- Pregnancy or intention to become pregnant during the next year
- Untreated hypothyroidism (defined as free thyroxine below the lower limit of normal)
- Active peptic ulcer disease
- Current use of medications known to effect theophylline levels (see protection of human subjects)
- History of hypersensitivity to theophylline or other medication components
- History of Major Depressive Disorder in the past 2 years, lifetime history of suicide attempt, history of any suicidal behavior in the past month, history of other sever psychiatric disorders (e.g. schizophrenia, bipolar disorder)
- PHQ-9 score is ≥15 or suicidal ideation of type 4 or 5 (C-SSR) in the past month
- Untreated hypothyroidism or uncontrolled PTH resistance (PTH >2x upper limit of normal), or treatment of these disorders by medications other than calcitriol or levothyroxine (such as Cytomel or Armour thyroid)
- Unable to comply with study procedures in the opinion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Theophylline
Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
|
oral theophylline
Other Names:
|
Placebo Comparator: Placebo
Placebo capsule by mouth once daily or Placebo elixir by mouth q6h
|
Placebo capsule or elixir
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body mass index
Time Frame: baseline and 52 weeks
|
BMI expressed as percent of the 95th percentile
|
baseline and 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in levothyroxine dose
Time Frame: baseline and 52 weeks
|
levothyroxine dose (mcg/kg/day)
|
baseline and 52 weeks
|
Change in calcitriol dose
Time Frame: baseline and 52 weeks
|
calcitriol dose (mcg/kg/day)
|
baseline and 52 weeks
|
Change in epiphyseal closure
Time Frame: baseline and 52 weeks
|
Bone age minus chronologic age
|
baseline and 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ashley Shoemaker, MD, Vanderbilt University Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Landreth H, Malow BA, Shoemaker AH. Increased Prevalence of Sleep Apnea in Children with Pseudohypoparathyroidism Type 1a. Horm Res Paediatr. 2015;84(1):1-5. doi: 10.1159/000381452. Epub 2015 Apr 23.
- Shoemaker AH, Juppner H. Nonclassic features of pseudohypoparathyroidism type 1A. Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):33-38. doi: 10.1097/MED.0000000000000306.
- Wang L, Shoemaker AH. Eating behaviors in obese children with pseudohypoparathyroidism type 1a: a cross-sectional study. Int J Pediatr Endocrinol. 2014;2014(1):21. doi: 10.1186/1687-9856-2014-21. Epub 2014 Oct 15.
- Mano T, Uchimura K, Hayashi R, Kobahashi T, Fujiwara K, Makino M, Kakizawa H, Nagata M, Nakai A, Wada M, Nagasaka A, Itoh M. Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor. Horm Metab Res. 1999 Nov;31(11):602-5. doi: 10.1055/s-2007-978804.
- Perez KM, Lee EB, Kahanda S, Duis J, Reyes M, Juppner H, Shoemaker AH. Cognitive and behavioral phenotype of children with pseudohypoparathyroidism type 1A. Am J Med Genet A. 2018 Feb;176(2):283-289. doi: 10.1002/ajmg.a.38534. Epub 2017 Nov 28.
- Curley KL, Kahanda S, Perez KM, Malow BA, Shoemaker AH. Obstructive Sleep Apnea and Otolaryngologic Manifestations in Children with Pseudohypoparathyroidism. Horm Res Paediatr. 2018;89(3):178-183. doi: 10.1159/000486715. Epub 2018 Feb 16.
- Hanna P, Grybek V, Perez de Nanclares G, Tran LC, de Sanctis L, Elli F, Errea J, Francou B, Kamenicky P, Linglart L, Pereda A, Rothenbuhler A, Tessaris D, Thiele S, Usardi A, Shoemaker AH, Kottler ML, Juppner H, Mantovani G, Linglart A. Genetic and Epigenetic Defects at the GNAS Locus Lead to Distinct Patterns of Skeletal Growth but Similar Early-Onset Obesity. J Bone Miner Res. 2018 Aug;33(8):1480-1488. doi: 10.1002/jbmr.3450. Epub 2018 Jun 7.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 13, 2020
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
September 9, 2020
First Submitted That Met QC Criteria
September 9, 2020
First Posted (Actual)
September 16, 2020
Study Record Updates
Last Update Posted (Actual)
April 2, 2024
Last Update Submitted That Met QC Criteria
April 1, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Bone Diseases
- Metabolism, Inborn Errors
- Bone Diseases, Metabolic
- Calcium Metabolism Disorders
- Metal Metabolism, Inborn Errors
- Pseudohypoparathyroidism
- Pseudopseudohypoparathyroidism
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Theophylline
Other Study ID Numbers
- IND 133103 R01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pseudohypoparathyroidism Type 1a
-
Connecticut Children's Medical CenterJohns Hopkins University; Eunice Kennedy Shriver National Institute of Child... and other collaboratorsRecruitingAlbright Hereditary Osteodystrophy | Pseudopseudohypoparathyroidism | Pseudohypoparathyroidism Type 1AUnited States
-
Children's Hospital of PhiladelphiaTerminatedAlbright Hereditary Osteodystrophy | Pseudohypoparathyroidism Type 1AUnited States
-
Ashley ShoemakerEnrolling by invitationPseudohypoparathyroidism Type 1a | Albright Hereditary Osteodystrophy | PseudohypoparathyroidismUnited States
-
Vanderbilt University Medical CenterMassachusetts General HospitalCompletedPseudohypoparathyroidism Type 1a | Albright Hereditary OsteodystrophyUnited States
-
Vanderbilt University Medical CenterTerminatedAlbright Hereditary Osteodystrophy | Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism | Pseudohypoparathyroidism Type IaUnited States
-
Oregon Health and Science UniversityAlaska Department of Health and Social ServicesCompletedCarnitine Palmitoyl Transferase Type 1A (CPT1A) DeficiencyUnited States
-
University of MilanEli Lilly and CompanyUnknownGrowth Hormone Deficiency, Dwarfism | PseudohypoparathyroidismItaly
-
University Hospital, Clermont-FerrandActive, not recruitingCharcot-Marie-Tooth Type 1A NeuropathyFrance
-
University Hospital, Clermont-FerrandCompletedCharcot-Marie-Tooth Type 1A NeuropathyFrance
Clinical Trials on Theophylline
-
Ashley ShoemakerEnrolling by invitationPseudohypoparathyroidism Type 1a | Albright Hereditary Osteodystrophy | PseudohypoparathyroidismUnited States
-
The First Affiliated Hospital of Guangzhou Medical...Completed
-
Medical College of WisconsinUniversity of OklahomaRecruitingAcute Kidney Injury | HIEUnited States
-
Washington University School of MedicineCompletedCovid19 | Anosmia | SARS-CoV-2 Infection | Olfactory Disorder | Ageusia | Covid-19 Pandemic | Hyposmia | HypogeusiaUnited States
-
University of MiamiNational Heart, Lung, and Blood Institute (NHLBI)CompletedCOPD | COPD Exacerbation | Pollution; Exposure | COPD Exacerbation Acute | Pollution Related Respiratory DisorderUganda
-
Zhujiang HospitalCompletedChronic Obstructive Pulmonary Disease | AsthmaChina
-
Boehringer IngelheimCompleted
-
Technical University of MunichCompletedRadiographic Contrast Agent Nephropathy
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); North Central Cancer Treatment GroupCompletedLeukemiaUnited States, South Africa, Puerto Rico
-
The George InstituteNational Health and Medical Research Council, AustraliaCompletedChronic Obstructive Pulmonary DiseaseAustralia